A diagnostic circulating miRNA signature as orchestrator of cell invasion via TKS4/TKS5/EFHD2 modulation in human gliomas.

Bianca Pollo, Maria Giulia Rizzo, Giulia Regazzo, Elisabetta Ferretti, Agnese Po, Veronica Villani, Stefano Scalera, Chiara Mandoj, Emilio Ciusani, Giorgia Simonetti, Sara Ramponi, Carlo Garufi, Ana Belén Díaz Méndez, Antonio Silvani, Giulia Vari, Marta Di Giuliani, Mariantonia Carosi, Frauke Goeman, Laura Rosanò, Valentina Caprara, Valentina Lulli, Elisa Tremante, Andrea Sacconi

Journal: Journal of experimental & clinical cancer research : CR 2023;42(1):66

PMID: 36932446

Abstract

BACKGROUND

Altered microRNA profiles have been observed not only in tumour tissues but also in biofluids, where they circulate in a stable form thus representing interesting biomarker candidates. This study aimed to identify a microRNA signature as a non-invasive biomarker and to investigate its impact on glioma biology.

METHODS

MicroRNAs were selected using a global expression profile in preoperative serum samples from 37 glioma patients. Comparison between serum samples from age and gender-matched controls was performed by using the droplet digital PCR. The ROC curve and Kaplan-Meier survival analyses were used to evaluate the diagnostic/prognostic values. The functional role of the identified signature was assessed by gain/loss of function strategies in glioma cells.

RESULTS

A three-microRNA signature (miR-1-3p/-26a-1-3p/-487b-3p) was differentially expressed in the serum of patients according to the isocitrate dehydrogenase (IDH) genes mutation status and correlated with both patient Overall and Progression Free Survival. The identified signature was also downregulated in the serum of patients compared to controls. Consistent with these results, the signature expression and release in the conditioned medium of glioma cells was lower in IDH-wild type cells compared to the mutated counterpart. Furthermore, in silico analysis of glioma datasets showed a consistent deregulation of the signature according to the IDH mutation status in glioma tumour tissues. Ectopic expression of the signature negatively affects several glioma functions. Notably, it impacts the glioma invasive phenotype by directly targeting the invadopodia-related proteins TKS4, TKS5 and EFHD2.

CONCLUSIONS

We identified a three microRNA signature as a promising complementary or even an independent non-invasive diagnostic/prognostic biomarker. The signature displays oncosuppressive functions in glioma cells and impacts on proteins crucial for migration and invasion, providing potential targets for therapeutic intervention.

© 2023. The Author(s).

Address: Department of Research, Advanced Diagnostics and Technological Innovation, Translational Oncology Research Unit, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.; Biostatistics and Bioinformatics Unit, Clinical Trial Center, IRCCS Regina Elena National Cancer Institute, Rome, Italy.; Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.; Preclinical Models and New Therapeutic Agents Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.; Institute of Molecular Biology and Pathology (IBPM), National Research Council (CNR), Rome, Italy.; SAFU Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.; Pathology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.; PhD Program in Molecular Medicine, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.; Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.; Medical-Oncology Unit, San Camillo Forlanini Hospital, Rome, Italy.; Clinical Pathology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.; PhD Program in Cellular and Molecular Biology, Department of Biology, University of Rome "Tor Vergata", Rome, Italy.; Neuro-Oncology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.; Department of Experimental Medicine, Sapienza University, Rome, Italy.; Department of Research, Advanced Diagnostics and Technological Innovation, Translational Oncology Research Unit, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy. [email protected].; Department of Research, Advanced Diagnostics and Technological Innovation, Translational Oncology Research Unit, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy. [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.